B+
Bull case
25%
Probability
Target price
$49.00
Analysis reference price unavailable
Analysis 2026-08-31 · RankAlpha Sentiment Codex
PAHC
Phibro Animal HealthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-08-31 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-08-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-31
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+76.8
Score
AI commentary
The earnings release and stored earnings transcript provide strong primary operating evidence, but the post-print signal is mixed: FY2026 results were strong, while FY2027 growth guidance is modest and forward risks remain. The packet does not provide verified analyst revisions or a clean price-reaction attribution, so this is a cautious monitoring setup rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-08-31
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-26eventStrong FY2026 results reset the base, but FY2027 guidance implies slower growthMedium impact
Phibro reported FY2026 net sales of $1.518 billion, adjusted EBITDA of $255 million, and adjusted diluted EPS of $3.22, while guiding FY2027 sales to $1.55-$1.60 billion and adjusted EBITDA to $258-$268 million. The result is a strong operating base but a more modest forward growth profile [#SEC-8K-2026-08-26].
2026-09-30catalystBrazil antimicrobial uncertainty and MFA comparison risk remain post-print overhangsMedium impact
The company previously identified Brazilian antimicrobial regulatory changes as a risk to certain products [#SEC-8K-2026-05-06]. Earnings coverage also highlighted a difficult comparison in the acquired MFA portfolio and limited near-term visibility, leaving execution and mix risk elevated [#PR-EARNINGS-2026-08-27].
2027-06-30catalystAcquired MFA portfolio remains the main commercial growth leverHigh impact
Management described FY2026 as a year of record sales, improved execution, and stronger efficiency, while earnings-call coverage indicated the acquired MFA portfolio is expected to outpace overall company growth in FY2027 [#EARNINGS-TRANSCRIPT-2026Q4]. The thesis requires sustained demand and successful integration.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-31 • Updated nightlySource: Internal modelMethodology